Jefferies Lifts Price Target on ZIOPHARM (ZIOP) After Analyst Day

Article Stock Quotes (1) Comments (0)

Jefferies boosted its price target on ZIOPHARM Oncology (NASDAQ: ZIOP) from $6 to $7 following the comapny's recent R&D day.

At the event the company highlighted: (1) palifosfamide in STS and SCLC; (2) PFS as a validated endpoint for FDA full approval: & (3) early IL-12 DNA therapeutics.

The firm comments, "ZIOP expects Ph3 palifosfamide PFS data in 1st-line sarcoma by YE12, with Ph3 SCLC data in ~2014-2015. On recent FDA full approval of Votrient in Tx-experienced sarcoma, it notes FDA's clear policy shift in favor of PFS benefits for full approvability."

For an analyst ratings summary and ratings history on ZIOPHARM Oncology click here. For more ratings news on ZIOPHARM Oncology click here.

Shares of ZIOPHARM Oncology closed at $5.89 yesterday, with a 52 week range of $3.55-$6.25.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: BofA/Merrill Lynch Downgrades Cliffs Natural Resources (CLF) to Underperform
• Goldman Sachs Upgrades Mizuho Financial Group Inc. (MFG) to Buy
• UPDATE: Macquarie Downgrades Sprint (S) to Neutral

Create E-mail Alert Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?